Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene's Revlimid Thrives As First-Line Multiple Myeloma Treatment

This article was originally published in The Pink Sheet Daily

Executive Summary

Spurred by backing of physician opinion leaders, sales grow quickly ahead of first-line filing, which is expected in the second half of 2010.

You may also be interested in...



Market Snapshot: Multiple Myeloma Drugs Promise To Live Up To Hype

Spurred by the introduction of new and highly effective drugs that have vastly improved survival rates, the fast-moving myeloma market is becoming a very attractive sector in oncology

Market Snapshot: Multiple Myeloma Drugs Promise To Live Up To Hype

Spurred by the introduction of new and highly effective drugs that have vastly improved survival rates, the fast-moving myeloma market is becoming a very attractive sector in oncology

ASH Preview: Researchers Chase Winning Combination In Frontline Myeloma

At this year's American Society of Hematology meeting, scientists will present data suggesting a cocktail of Revlimid, Velcade and dexamethasone could emerge as the backbone of frontline therapy for multiple myeloma

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel